NIH Funding Shifts and Delays Impact Biomedical Research
Similar Articles
Former NIAID Advisor Charged with Hiding COVID-19 Records
Trump Administration Terminates National Science Board Members
NIH Bridge Funding Sustains Alzheimer's Research Network After Grant Rejection
House Oversight Committee Investigates Deaths and Disappearances of Scientists
HHS Confirms FDA Blocked Publication of Vaccine Studies
The National Institutes of Health (NIH) has shifted its grant-making strategy, resulting in fewer but larger awards and significant delays in the review process. This has forced researchers, including a prominent computational biologist, to lay off staff and has stalled critical pediatric cancer studies. While an administration spokesperson says timelines are returning to normal, an analysis shows a sharp drop in new grants issued.
Facts First
- NIH strategy has shifted toward fewer, larger grants, according to a former agency official.
- New grant awards dropped by 66% in early 2026 compared to the previous year, per a university association analysis.
- Many NIH funding forecasts are past their promised posting dates, with 205 of 336 listed as open being delayed.
- A pediatric cancer researcher's grant review has been stalled by repeatedly moved deadlines.
- An HHS spokesperson states funding timelines have returned to typical patterns after earlier delays.
What Happened
The National Institutes of Health (NIH) has changed its funding approach, making fewer grants with more money over longer periods, according to former NIH official Jeremy Berg. An analysis from the Association of American Universities showed the NIH issued 66 percent fewer grant awards in the first few months of 2026 compared to the previous year. Former NIH program officer Elizabeth Ginexi found that many NIH funding forecasts were past their promised posting date without a full announcement being published. This has created delays for research grants, such as for biomedical engineer Rachael Sirianni, whose grant to evaluate medications for pediatric metastatic brain cancer has not been reviewed due to repeatedly moved deadlines. Separately, Harvard computational biologist Sean Eddy had his federal funding terminated in 2025 after receiving a letter from the NIH stating his work was determined to be of no value to the taxpayer, leading him to let almost all of his lab staff go over the last year.
Why this Matters to You
Changes in federal research funding may slow the pace of discoveries for diseases like cancer and neurodevelopmental disorders. The software developed by Sean Eddy's team, now underfunded, is used in such research. Delays in reviewing grants could postpone potential new therapies. The shift toward fewer, larger grants may concentrate resources, which could make it harder for new scientists to secure funding and may lead to job losses in academic research labs.
What's Next
Andrew Nixon, a spokesperson for Health and Human Services (HHS), stated that funding timelines have returned to typical patterns after earlier delays attributed to a government shutdown and congressional Democrats. Some Republicans and Democrats made an effort in early 2026 to restore portions of funding cut the previous year, which suggests political attention to the issue. However, the long-term impact of the NIH's strategic shift and the backlog of delayed funding announcements may continue to affect research projects and employment in the biomedical sector for the foreseeable future.